Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Clinical trial shows gene editing works for β-Thalassaemia, too

The therapy produced more focused edits with fewer mistakes and builds on the first CRISPR treatment approved by the U.S. Food and Drug Administration.

Summary by Ars Technica
Improved gene editing process reactivates the fetal version of a hemoglobin gene.

2 Articles

PharmaphorumPharmaphorum
Center

Chinese trial backs base-editing drug for thalassaemia

A landmark study in China has shown that a base-editing therapy developed by CorrectSequence achieved stellar results in beta-thalassaemia

Read Full Article
Ars TechnicaArs Technica
Center

Clinical trial shows gene editing works for β-Thalassaemia, too

Improved gene editing process reactivates the fetal version of a hemoglobin gene.

·United States
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Ars Technica broke the news in United States on Thursday, April 9, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Genome Editing icon

Genome Editing

China icon

China

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal